This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus infection.
All eligible patients received prophylactic antiviral therapy during and within 6 months after chemotherapy in previous sudy. We did not assign specific interventions to the subjects in this study. The primary endpoint of this study is the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall survival rate.
Study Type
OBSERVATIONAL
Enrollment
107
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
the incidence of hepatitis B virus delayed reactivation
hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy
Time frame: within one year after withdrawal of prophylactic antiviral therapy
the incidence of hepatitis B virus related hepatitis flare
the incidence of hepatitis B virus related hepatitis flare after withdrawal of prophylactic antiviral therapy
Time frame: within one year after withdrawal of prophylactic antiviral therapy
Number of patients that achieve a tumor response
Time frame: within one year after withdrawal of prophylactic antiviral therapy
overall survival rate
Time frame: within one year after withdrawal of prophylactic antiviral therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.